Urogen Pharma Ltd. plans to launch its new product July 1 after the firm overcame a decidedly mixed FDA advisory panel meeting to nail down approval June 12 of Zusduri (mitomycin, formerly known as ...

Biopharma deal activity continued its record-breaking pace in 2025, reaching $103.76 billion in total value through the first five months, the highest year-to-date total in BioWorld’s records. That ...

FROM artificial intelligence to military defence, China has offered a few DeepSeek moments this year, showing that the ...

Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing ...

米Pfizer（ファイザー）社は2025年5月19日、中国の大手バイオ医薬品会社である3SBio社と、PD-1及び血管内皮成長因子（VEGF）を標的とする二重特異性抗体（開発番号：SSGJ-707）の、中国以外の世界各国における開発、製造、商業化に関 ...

Bristol-Myers makes an $11 billion deal with BioNTech to join the new cancer-treatment game, nearly double the size of Pfizer ...

A colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of China. As well as securing record sums in upfront and other fees, the ...